In this special episode on Hypercortisolism in Diabetes our host, Dr. Neil Skolnik, will discuss new evidence showing the surprising prevalence of Hypercortisolism in people with uncontrolled Type 2 Diabetes. This special episode is supported by an independent educational grant from Corcept.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John Buse MD – The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award,

Reference:

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care dc242841 https://doi.org/10.2337/dc24-2841

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals.

Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting.

Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.

This issue will review:

1. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - NEJM

2. Diabetes and Anemia – Diabetes Care

3. Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials – Diabetes Care

4. Cardiovascular and Kidney Outcomes and Mortality With Long- Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials – Diabetes Care

5. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - NEJM

For more information about each of ADA’s science and medical journals, please visit Diabetesjournals.org.

Hosts:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this special episode on Early Identification and Delay of Type 1 Diabetes, Dr. Neil Skolnik this emerging area with Dr. Jay Shubrook. This special episode is supported by an independent educational grant from Sanofi.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Jay Shubrook, D.O. - Professor and Director of Diabetes Services, Touro University. Past Chair, The American Diabetes Association Primary Care Advisory Group, Past Chair of the American College of Diabetology.

Selected References and Resources referred to the in the Podcast:

Webinar Registration (Apr 28, 2025 10:00 AM):

Early Detection Saves Lives: Implementing Type 1 Diabetes Screening in Pediatric and Primary Care

References:

Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 2024;47(8):1276–1298

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381:603-613

Resources for Auto-antibody Testing:

Type 1 Diabetes TrialNet Centers of Excellence Locations

Type 1 Risk test

Trialnet